Reactive arthritis epidemiology and demographics

	Reactive arthritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Reactive arthritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Reactive arthritis epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Reactive arthritis epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Reactive arthritis epidemiology and demographics
CDC on Reactive arthritis epidemiology and demographics
Reactive arthritis epidemiology and demographics in the news
Blogs onReactive arthritis epidemiology and demographics
Directions to Hospitals Treating Reactive arthritis
Risk calculators and risk factors forReactive arthritis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:

Overview

The incidence of reactive arthritis following a gastrointestinal or genitourinary infection is approximately 1-3.1 cases per 100,000 individuals worldwide.^[1]
The incidence rate of reactive arthritis varies with the underlying infection.^[2]
- The incidence rate of reactive arthritis following Campylobacter infection is 900 per 100,000 cases.
- The incidence rate of reactive arthritis following Salmonella and Shigella infection is 1200 per 100,000 cases.

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

There is no racial predilection to [disease name].
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Reactive arthritis affects men and women equally.
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

↑ Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J (December 2008). "Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study". Ann. Rheum. Dis. 67 (12): 1689–96. doi:10.1136/ard.2007.083451. PMID 18272671.
↑ Ajene AN, Fischer Walker CL, Black RE (September 2013). "Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis". J Health Popul Nutr. 31 (3): 299–307. PMC 3805878. PMID 24288942.